Market Data
Register to chat with like-minded investors on our interactive forums.
Evaxion Biotech AS (NASDAQ:EVAX) shares surged 10.6% on Thursday after the clinical-stage TechBio company revealed promising advances in its cytomegalovirus (CMV) vaccine candidate, EVX-V1.
The Copenhagen-based firm said its AI-Immunology™ discovery system has identified a new set of CMV antigens that markedly reduce viral activity in preclinical testing. These previously unexplored antigens produced targeted immune responses, blocked viral infection, and limited cell-to-cell transmission in both cell-based and animal infection models.
EVX-V1 integrates these fresh AI-derived antigens with AI-enhanced versions of traditional CMV vaccine components. Notably, Evaxion’s proprietary AI-optimized pre-fusion glycoprotein B (gB) antigen outperformed conventional gB antigens, demonstrating stronger CMV neutralization.
“We are very excited by the new data demonstrating the unique capability of AI-Immunology™ to find novel protective vaccine targets where no others have been able to do so,” said Birgitte Rønø, CSO and interim CEO of Evaxion.
The company continues to progress EVX-V1 through preclinical development, expanding its analysis and refinement of the antigens. At the same time, Evaxion is evaluating partnership opportunities to help accelerate the program toward non-clinical and clinical testing stages.
Despite decades of research, CMV still lacks an approved vaccine and remains a major unmet medical challenge. Evaxion’s multi-antigen approach is designed to broaden the potential protection of its candidate by targeting the virus through multiple complementary mechanisms.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.
Tesla (NASDAQ:TSLA) has launched a lower-cost version of its Model 3 sedan in Europe, several months after debuting the same variant in the United States, according to updated pricing on the company’s website. The new Model 3 Standard is designed to bolster demand across the region, where rising competition from European and Chinese automakers has […]
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
